Frey Dietmar, Schilt Sarah, Strack Valérie, Zdunczyk Anna, Rösler Judith, Niraula Birat, Vajkoczy Peter, Picht Thomas
Department of Neurosurgery, Charité University Medicine, Berlin, Germany.
Neuro Oncol. 2014 Oct;16(10):1365-72. doi: 10.1093/neuonc/nou110. Epub 2014 Jun 12.
Neurological and oncological outcomes of motor eloquent brain-tumor patients depend upon the ability to localize functional areas and the respective proposed therapy. We set out to determine whether the use of navigated transcranial magnetic stimulation (nTMS) had an impact on treatment and outcome in patients with brain tumors in motor eloquent locations.
We enrolled 250 consecutive patients and compared their functional and oncological outcomes to a matched pre-nTMS control group (n = 115).
nTMS mapping results disproved suspected involvement of primary motor cortex in 25.1% of cases, expanded surgical indication in 14.8%, and led to planning of more extensive resection in 35.2% of cases and more restrictive resection in 3.5%. In comparison with the control group, the rate of gross total resections increased significantly from 42% to 59% (P < .05). Progression-free-survival for low grade glioma was significantly better in the nTMS group at 22.4 months than in control group at 15.4 months (P < .05). Integration of nTMS led to a nonsignificant change of postoperative deficits from 8.5% in the control group to 6.1% in the nTMS group.
nTMS provides crucial data for preoperative planning and surgical resection of tumors involving essential motor areas. Expanding surgical indications and extent of resection based on nTMS enables more patients to undergo surgery and might lead to better neurological outcomes and higher survival rates in brain tumor patients. The impact of this study should go far beyond the neurosurgical community because it could fundamentally improve treatment and outcome, and its results will likely change clinical practice.
运动功能区明确的脑肿瘤患者的神经学和肿瘤学预后取决于功能区定位能力及相应的治疗方案。我们旨在确定导航经颅磁刺激(nTMS)的应用是否会对运动功能区明确的脑肿瘤患者的治疗及预后产生影响。
我们连续纳入了250例患者,并将其功能和肿瘤学预后与匹配的nTMS应用前对照组(n = 115)进行比较。
nTMS映射结果在25.1%的病例中排除了对初级运动皮层的可疑累及,在14.8%的病例中扩大了手术指征,在35.2%的病例中促使计划进行更广泛的切除,在3.5%的病例中促使计划进行更保守的切除。与对照组相比,大体全切率从42%显著提高到59%(P < .05)。低级别胶质瘤患者的无进展生存期在nTMS组为22.4个月,显著优于对照组的15.4个月(P < .05)。nTMS的应用使术后神经功能缺损从对照组的8.5%非显著变化至nTMS组的6.1%。
nTMS为涉及重要运动区的肿瘤的术前规划和手术切除提供了关键数据。基于nTMS扩大手术指征和切除范围能使更多患者接受手术,并可能改善脑肿瘤患者的神经学预后和提高生存率。本研究的影响应远超神经外科领域,因为它可能从根本上改善治疗及预后,其结果可能会改变临床实践。